Results 161 to 170 of about 101,541 (346)

Learning Optimal Dynamic Treatment Regimes from Longitudinal Data [PDF]

arXiv
Studies often report estimates of the average treatment effect. While the ATE summarizes the effect of a treatment on average, it does not provide any information about the effect of treatment within any individual. A treatment strategy that uses an individual's information to tailor treatment to maximize benefit is known as an optimal dynamic ...
arxiv  

Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review

Substance Abuse and Rehabilitation, 2017
Christa R Lewis,1,2 Hoa T Vo,1 Marc Fishman1,3 1Maryland Treatment Centers, Baltimore, MD, USA; 2Department of Psychology, Towson University, Towson, MD, USA; 3Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA Abstract ...
Lewis CR, Vo HT, Fishman M
doaj  

Understanding Drug and Alcohol Staff Perspectives on the Barriers and Facilitators to Drug Checking: A Qualitative Study

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction Drug checking (i.e., whereby members of the public submit a drug sample for pharmacological analysis of the drug content) is an evidence‐based harm reduction tool. Despite this, the uptake of drug checking services by people who use drugs (PWUD) is often limited across different jurisdictions and types of services, highlighting ...
Nina Pocuca, Brodie C. Dakin, Cheneal Puljević, Cameron Francis, Daniel Stjepanović, Anthony Barnett, Leanne Hides   +6 more
wiley   +1 more source

Autoregressive models for panel data causal inference with application to state-level opioid policies [PDF]

arXiv
Motivated by the study of state opioid policies, we propose a novel approach that uses autoregressive models for causal effect estimation in settings with panel data and staggered treatment adoption. Specifically, we seek to estimate of the impact of key opioid-related policies by quantifying the effects of must access prescription drug monitoring ...
arxiv  

Cerebral Metabolic Effects of Naloxone [PDF]

, 1979
Alan A. Artru, Petter Andreas Steen, John D. Michenfelder   +2 more
openalex   +1 more source

A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?

Drug and Alcohol Review, EarlyView.
ABSTRACT Issues Rising synthetic opioid deaths in North America, and the emergence of nitazene harms has driven concern about novel synthetic opioids (NSO) in Australia. This scoping review aimed to map what is known about NSOs in Australia. Approach Scoping review of peer‐reviewed and grey literature on NSO detections and harms.
Emmanuel Mammoliti, Suzanne Nielsen, Amanda Roxburgh   +2 more
wiley   +1 more source

The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City

Drug and Alcohol Dependence Reports, 2022
Background: Naloxone distributed to people at risk for opioid overdose has been associated with reduced overdose death rates; however, associations of retail pharmacy-distributed naloxone with overdose mortality have not been evaluated.
Jake R. Morgan, Christina E. Freibott, Ali Jalali, Philip J. Jeng, Alexander Y. Walley, Avik Chatterjee, Traci C. Green, Michelle L. Nolan, Benjamin P. Linas, Brandon D.L. Marshall, Sean M. Murphy   +10 more
doaj  

Use of naloxone in opiate poisoning. [PDF]

, 1973
L.E. Evans
openalex   +1 more source

Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short‐Acting Injectable Opioid Treatment in Australia

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction A growing body of qualitative scholarship has drawn attention to aspects of supervised injectable opioid treatment (SIOT) not captured in earlier clinical trial data, identifying treatment initiation as one such area. Crucial questions surrounding people's motivations, expectations and initial experiences of SIOT remain under ...
Jake Rance, Vendula Belackova, James Bell, Adrian J. Dunlop, Nadine Ezard, Marianne Jauncey, Nicholas Lintzeris, Eugenia Oviedo‐Joekes, Alison Ritter, Darren M. Roberts, Craig Rodgers, Krista J. Siefried, John Strang, Willem van den Brink, Carla Treloar   +14 more
wiley   +1 more source

A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions

Economic Inquiry, EarlyView.
Abstract In their 2022 study, ‘The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime,’ Doleac and Mukherjee conclude that broadening access to a life‐saving drug—naloxone—does not reduce opioid‐related mortality as the drug simultaneously encourages riskier drug use. I show issues with their data, design, and estimation methods. For
Sergey Alexeev
wiley   +1 more source